Nektar Therapeutics (NASDAQ:NKTR) Receives $2.33 Consensus Price Target from Analysts
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has received an average recommendation of “Hold” from the seven brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month […]
7 Nov 03:54 · The Cerbat Gem